SHANDONG LUKANG PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.92 CNY | +0.17% |
|
-1.17% | -17.09% |
| Mar. 22 | Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 25 | Lukang Pharmaceutical Gets Nod to Produce Parkinson's Disease Drug | MT |
| Sales 2022 | 5.62B 776M | Sales 2023 | 6.15B 849M | Capitalization | 6.36B 879M |
|---|---|---|---|---|---|
| Net income 2022 | 138M 19.06M | Net income 2023 | 246M 33.98M | EV / Sales 2022 | 1.53 x |
| Net Debt 2022 | 2.16B 299M | Net Debt 2023 | 2.08B 287M | EV / Sales 2023 | 1.37 x |
| P/E ratio 2022 |
48.4
x | P/E ratio 2023 |
25.5
x | Employees | 6,484 |
| Yield 2022 |
0.69% | Yield 2023 |
1.26% | Free-Float | 73.25% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.17% | ||
| 1 week | -1.17% | ||
| Current month | -4.05% | ||
| 1 month | -7.93% | ||
| 3 months | -7.93% | ||
| 6 months | -10.03% | ||
| Current year | -17.09% |
1 week
5.67
6.04
1 month
5.676.54
Current year
5.047.28
1 year
5.049.03
3 years
5.049.03
5 years
5.0418.35
10 years
3.6619.81
| Managers | Title | Age | Since |
|---|---|---|---|
Kun Dong
CEO | Chief Executive Officer | 55 | 21-05-18 |
Li Li
DFI | Director of Finance/CFO | 58 | 16-02-29 |
Xin Peng
CHM | Chairman | 51 | 94-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hao Dong Qi
BRD | Director/Board Member | 64 | 21-05-18 |
Zi Xin Deng
BRD | Director/Board Member | 67 | 21-05-18 |
Xin Peng
CHM | Chairman | 51 | 94-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 5.92 | +0.17% | 9,934,422 |
| 24-04-18 | 5.91 | -0.34% | 11,092,060 |
| 24-04-17 | 5.93 | +3.49% | 15,685,400 |
| 24-04-16 | 5.73 | -2.88% | 21,928,320 |
| 24-04-15 | 5.9 | -1.50% | 16,585,410 |
End-of-day quote Shanghai S.E., April 18, 2024
More quotes
Shandong Lukang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company's primary products include pharmaceutical preparation products, semi-synthetic antibiotic raw materials, veterinary antibiotics and antibiotic raw materials and others. The Company is also involved in the production and distribution of pharmaceutical intermediates. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.09% | 732M | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- 600789 Stock
